Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells

Clinical Cancer Research

Volumn 2, Issue 10, 1996, Pages 1649-1657

  Yang, Bin ^a,b   Eshleman, James R ^a,b   Berger, Nathan A ^a,b   Markowitz, Sanford D ^a,b,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c Ireland Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; PROTEIN P53; TOPOTECAN;

ARTICLE; COLON CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG RESISTANCE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DEATH; COLONIC NEOPLASMS; FLUOROURACIL; HUMANS; ISOPROPYL THIOGALACTOSIDE; TIME FACTORS; TOPOTECAN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029962567     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991
2. Levine, A., Momand, J., and Finlay, C. The p53 tumor suppressor gene. Nature (Lond.), 351: 453-456, 1991.
3. Baker, S., Fearon, E., Nigro, J., Hamilton, S., Preisinger, A., Jessup, J., VanTuinen, P., Ledbetter, D., Barker, K., Nakamura, Y., White, R., and Vogelstein, B. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science (Washington DC), 244: 217, 1989.
4. Kastan, M., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991
5. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587-597, 1992.
6. Kuerbitz, S., Plunkett, B., Walsh, W., and Kastan, M. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
7. Diller, L., Kassel, J., Nelson, C. E., Gryka, M. A., Litwak, G., Gabhardt, M., Bressac, B., Ozturk, M., Baker, S. J., Vogelstein, B., and Friend, S. H. p53 functions as cell cycle control protein in osteosarcomas. Mol. Cell. Biol., 10: 5772-5781, 1990.
8. Mercer, W., Shields, M., Amin, M., Sauve, G., Appella, E., Romano, J., and Ullrich, S. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc. Natl. Acad. Sci. USA, 87: 6166-6170, 1990.
9. Hartwell, L., and Kastan, M. Cell cycle control and cancer. Science (Washington DC), 266: 1821-1828, 1994.
10. Lowe, S., Schmitt, E., Smith, S., Osborne, B., and Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847-849, 1993.
11. Ramqvist, T., Magnuson, K., Wang, Y., Szekeley, L., and Klein, G. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene, 8: 1495-1500, 1993.
12. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Saches, L., Kimchi, A., and Oren, M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (Lond.), 352, 345-347, 1991.
13. Debbas, M., and White, E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev., 7: 546-554, 1993.
14. Lowe, S., and Ruley, H. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev., 7: 535-545, 1993.
15. Symonds, H , Krall, L., Remington, L., Robles-Saenz, M., Lowe, S., Jacks, T., and Van Dyke, T. p53-dependent apoptosis suppresses tumor growth and progression in vivo Cell, 78. 703-711, 1994.
16. Shaw, P., Bovey, R., Tardy, S., Sahli, R., Soada, B., and Costa, J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. USA, 89: 4495-4499, 1992.
17. Fan, S., Smith, M , Rivet, D., II, Duba, D., Zhan, Q., Kohn, K., Fornace, A., and O'Connor, P. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995.
18. Hawkins, D., Demers, W., and Galloway, D. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56: 892-898, 1996.
19. Lowe, S., Bodis, S., McClatchey, A., Remington, L., Ruley, H., Fisher, D., Housman, D., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
20. Nabeya, Y., Loganzo, J. F, Maslak, P., Lai, L., De Oliveira, A., Schwartz, G., Blundell, M., Altorki, N., Kelsen, D., and Albino, A. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int. J. Cancer, 64: 37-46, 1995.
21. O'Connor, P., Jackman, J., Jondle, D., Bhatia, K., Magrath, I., and Kohn, K. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res., 53: 4776-4780, 1993.
22. Perego, P., Giarola, M., Righetti, S., Supino, R., Caserini, C , Delia, D., Pierotti, M., Miyashita, T., Reed, J., and Zunino, F. Association between cisplatin resistance and mutation of p53 gene and reduced expression in ovarian carcinoma cell systems. Cancer Res., 56: 556-562, 1996.
23. Righetti, S., Della Torre, G., Pilotti, S., Menard, S., Ottone, F., Colnaghi, M., Pierotti, M., Lavarino, C., Cornarotti, M., Oriana, S., Bohm, S., Bresciani, G., Spatti, G., and Zunino, F. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res., 56: 689-693, 1996.
24. Slichenmyer, W., Nelson, W., Slebos, R , and Kastan, M. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res., 55: 4164-4168, 1993.
25. Cohen, A., Shank, B., and Friedmen, M. Colorectal cancer. In. V. DeVita, S. Hellman, and S. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, pp. 895-964. Philadelphia: J. B. Lippincott, 1989.
26. Baker, S., Preisinger, A., Jessup, J., Paraskeva, C., Markowitz, S., Willson, J., Halmiton, S., and Vogelstein, B. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res., 50: 7717-7722, 1990.
27. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Washington DC), 249: 912-915, 1990
28. Yang, B., Stambrook, P., and Markowitz, S. Wild-type p53 demonstrates functional dominance in a human colon carcinoma cell line in which it induces reversible growth arrest. Clin. Cancer Res., 2: 1639-1647, 1996.
29. Compton, M., and Cidlowski, J. Rapid in vivo effects of glucocorticoid on the integrity of rat lymphocyte genomic deoxyribonucleic acid. Endocrinology, 118: 38, 1986.
30. Houghton, P., Cheshire, P., Myers, L., Stewart, C., Synold, P., and Houghton, J. Evaluation on 9-dimethylaminomethyl-10-hydroxycamptothecin (topotecan) against xenografts derived from adult and childhood tumors. Cancer Chemother. Pharmacol., 31: 229-239, 1992.
31. Johnson, R., McCabe, F., Faucette, L., Hertzberg, R., and Kingsbury, W. SKF 104864, a water-soluble analog of camptothecin with broad-spectrum activity in preclinical tumor models. Proc. Am. Assoc. Cancer Res., 30: 623, 1989.
32. Elledge, R., Lock-Lim, S., Allred, D., Hilsenbeck, S., and Cordner, L. p53 mutation and tamoxifen resistance in breast cancer. Clin. Cancer Res., 1: 1203-1208, 1995.
33. Chen, P-L., Chen, Y., Bookstein, R., and Lee, W-H. Genetic mechanisms of tumor suppression by the human p53 gene. Science (Washington DC), 250: 1576-1580, 1990.
34. Fujiwara, T., Grimm, E., Mukhopadhyay, T., Zhang, W-W., Owen-Schaub, L., and Roth, J. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 1994: 2287-2291, 1994.
35. Gjerset, R., Turla, S., Sobol, R., Scalise, J., Mercola, D., Collins, H., and Hopkins, P. Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol. Carcinog., 14: 275-285, 1995.
36. Vikhanskaya, F., D'Incalci, M., and Broggini, M. Decreased cytotoxic effects of doxorubicin in a human ovarian cancer cell line expressing wild-type p53 and WAF1/CIP1 genes. Int. J. Cancer, 61: 397-401, 1995.
37. Abarzua, P , LoSardo, J., Gubler, M., and Neri, A. Microinjection of monoclonal antibody pAb421 into human SW480 colorectal carcinoma cells restores the transcriptional activation function to mutant p53. Cancer Res., 55: 3490-3494, 1995.
38. Rusch, V., Klimstra, D., Venkatraman, E., Oliver, J., Martini, N., Gralla, R., Kris, M., and Dmitrovsky, E. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res., 55: 5038-5042, 1995.
39. Fan, S., El-Deiry, W., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fornace, A., Magrath, I., Kohn, K., and O'Connor, P. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54: 5824-5830, 1994.
40. Ryan, J., Prochownik, E., Gottlieb, C., Apel, I., Merino, R., Nunez, G., and Clarke, M. C-myc and bcl2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc. Natl. Acad. Sci. USA, 91: 5878-5882, 1994.
41. Gomez-Manzano, C., Fueyo, J., Kyritsis, A., Steck, P., Roth, J., McDonnell, J., Steck, K., Levin, V., and Yung, W. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res., 56: 694-699, 1996.
42. Liu, T-J., Zhang, W-W., Taylor, D., Roth, J , Goepfert, H., and Clayman, G. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenoviras. Cancer Res., 54: 3662-3667, 1994.